Yellow headers = a website page
(with a button on the top nav bar)

Green = Section within a page

Image Notes: Criteria for an image for a particular section

Black font like this is copy that will appear on each section

CTA BUTTON that Links to either another page on the site or an external link

video

Home

Hero image: Norwegian Cancer patient (Scandinavian looking/and setting)

Tagline: Oncolytic Molecules that Kill Cancer & Prevent Recurrence

SubTagline: Neoadjuvant Immunotherapy with Durable Responses Approaching Commercialization

Section 1: Lytix Biopharma is Redefining the Standard of Care in the Neoadjuvant Setting with First-in-class First Line Immunotherapies

Image: 

Lytix Biopharma is developing a pipeline of oncolytic molecule therapies that treat both superficial and deep-seated tumors. Our focus is to re-define the standard of care in the neoadjuvant setting, through providing patients with first-in-class, first-line immunotherapies that kill cancer and prevent recurrence. Our mission is to deliver transformative medicines that work in synergy with immune checkpoint inhibitors, to offer patients the best outcomes as fast as possible.

Link to About Page

Section 2: Our Oncolytic Molecule Drugs Overcome Immunosuppression Within the Tumor Microenvironment

Image: 

Lytix Biopharma has built an oncolytic molecule platform that overcomes immunosuppression within the tumor microenvironment via a two-step mode of action. Our drugs destroy the membranes of cancer cells, releasing both tumor antigens and potent immunostimulatory molecules that initiate a broad immune cell response. The resulting immune cell infiltration into the tumor microenvironment delivers broad and durable anti-tumor immunity.

Link to Science Page

Section 3: Our Partner-ready Pipeline is Led by Ruxotemitide, Which is Rapidly Approaching Commercialization

Pipeline teaser as per Spyre below: clip the teaser to show only top 2



Link to Pipeline Page

Section 4: Learn More About Our Deep Clinical Trial Validation

Norwegian Cancer Patient (female in 40's- outdoors active/ fishing?)

Lytix Biopharma has completed multiple Phase 2 trials, and is currently enrolling patients in an investigator-led Phase 2 study, NeoLIPA which is evaluating ruxotemitide (formerly LTX-315) in combination with pembrolizumab in resectable melanoma patients in the neoadjuvant setting.

Link to Clinical Trials Page

Section 5: Our Partnering Strategy is Built to Deliver Commercial Success

Image similar to this: 

IMAGE in dr coat/ doctor look - - Asian man 40’s

Interested in learning more about our assets? At Lytix Biopharma we are open to discussions on co-development and outlicensing opportunities.

Current Partnership:
Verrica Pharmaceuticals - Currently assessing ruxotemititide (VP-315) in a Phase 2 study in basal cell carcinoma.
Click here to see the latest positive results from this study Link to https://newsweb.oslobors.no/message/659147

Section 6: Investor Relations
No art
3 most recent press releases

About Page

No art

Dropdown 1 - Management Team - all photos and bios- ask LYT if want to update bios
Add cta’s to the other team pages top and bottom

No art
Copy info from current website: https://www.lytixbiopharma.com/about/management-team.html
Add Karim (CMO)

Dropdown 2 - Board of Directors - all photos and bios- ask LYT if want to update bios
Add cta’s to the other team pages top and bottom
No art
Copy info from current website:
https://www.lytixbiopharma.com/about/board-of-directors.html

Dropdown 3 - Clinical Advisory Board - all photos and bios- ask LYT if want to update bios
Add cta's to the other team pages top and bottom

No art
Copy info from current website:
https://www.lytixbiopharma.com/about/advisory-board.html
Replace Robert Andtbacka with James Wooldridge

Science

Image: 

MAKE THE FOLLOWING 3 SECTIONS PRETTY/NOT JUST TEXT AND NOT BULLETS AND PROBABLY MORE TEXT COMING FROM OYSTEIN?

Section 1 - Most patients won't respond to Immune checkpoint inhibitors

Immune checkpoint inhibitors have revolutionized cancer treatment, but many patients fail to respond to immune checkpoint inhibitors, and this lack of response is driven by three key factors.
Box 1: acquired immunotherapy resistance from multiple lines of treatment
Box 2: tumor heterogeneity and low mutational burden
Box 3: low PD-L1 expression and limited T-cell infiltration of the tumor microenvironment.

Section 2 - Our oncolytic molecule therapies address the limitations of immune checkpoint inhibitors and enhance their clinical impact

MAKE THE FOLLOWING 3 SECTIONS PRETTY/NOT JUST TEXT AND NOT BULLETS AND PROBABLY MORE TEXT COMING FROM OYSTEIN?

Box 1: Active against immunotherapy resistant cancer cells
Box 2: Tumor response is independent of tumor heterogeneity and mutational burden
Box 3: Broad T-cell response and infiltration into the tumor microenvironment is PD-L1 independent

Section 3 - Our Unique Two-step mode of action

DS WILL RECREATE THE BELOW DESIGN WITH SAME ART



Section 4 - Publications
MSC (internal note: DH pull all current items from OG site- significant number)
Copy info from current website: https://www.lytixbiopharma.com/publications

Section 5 - Posters
(MSC internal note: DH pull all current items from OG site- significant number)

Copy info from current website: https://www.lytixbiopharma.com/posters

Pipeline
MSC INTERNAL NOTE: same pipeline as MEDIC with left box 1 line copy

Partner-ready Pipeline

Lytix holds an extensive patent estate protecting its proprietary anti-tumor molecules and their application in immunotherapy across major pharmaceutical markets.



Section 1 - Ruxotemitide (LTX-315)

MSC internal note: Left Box COPY duplicate for top 3 assets: **Ruxotemitide has consistently delivered strong tumor activity, excellent tolerability and clear systemic immune engagement in Phase 2 trials.**

Ruxotemitide is an oncolytic peptide that has consistently delivered strong tumor activity, excellent tolerability and clear systemic immune engagement in Phase 2 trials. As a monotherapy, ruxotemitide enables rapid tumor destruction, robust immune cell infiltration and complete regression in injected tumors. Ruxotemitide also delivers abscopal effects in distant metastases, demonstrating clear systemic immune activation.

In combination with immune checkpoint inhibitors, ruxotemitide affords disease control in patients who had previously failed immune checkpoint inhibitor therapy, indicating the impact ruxotemitide can have on the current standard of care for many cancers in the neoadjuvant setting.

Ruxotemtidie is currently being evaluated in an investigator-initiated Phase 2 study ‘NeoLIPA’ in patients with resectable melanoma prior to surgery.

Section 2 - LTX-401

MSC internal note: Left Box COPY for bottom asset 401:: **LTX-401 is an oncolytic molecule designed for deep-seated tumors.**

LTX-401 expands our oncolytic molecule platform into deep-seated tumors through image-guided intratumoral delivery. This opens access to the liver and other internal tumors where intratumoral treatment has historically not been feasible.

LTX-401 has demonstrated strong proof-of-concept in multiple difficult-to-treat cancer models, including curing animals of liver cancer, and is currently in last-stage pre-clinical development.

Patient Resources

Patient image (Male in 60's outdoors- scandinavian setting)

Section 1:

Lytix needs to guide on what resources to add

Clinical Trials

Patient and Dr image

Section 1: NeoLIPA

An investigator-initiated Phase 2 study with ruxotemitide is currently underway at the Oslo University Hospital. This study is exploring neo-adjuvant ruxotemitide (administered before surgery) in combination with standard of care pembrolizumab (KEYTRUDA®) in patients with resectable melanoma. The objective of this study is to demonstrate that ruxotemtidie improves outcomes in these patients and prevents disease recurrence.

Link to:https://clinicaltrials.gov/study/NCT06651151?term=NEOLIPA&rank=1

Section 2: Verrica Pharmaceuticals sponsored Phase II Study in Basal Cell Carcinoma

Verrica has generated impressive Phase 2 data in basal cell carcinoma with ruxotemitide as a monotherapy. They have reported a 51% complete response rate, and clinical responses in 97% of the patients with significant reduction of tumor size.

Additionally, Verrica has demonstrated that ruxotemitide reprograms the tumor microenvironment, with patients biopsies showing significant increases in CD4+, CD8+ T cells, and B-cells, indicating strong recruitment of effector immune populations into the tumor.

Link to:https://clinicaltrials.gov/study/NCT05188729?term=VP-315&rank=1

Partnerships

Interleukin art

Section 1: Verrica Pharmaceuticals Add Verrica Logo

Verrica Pharmaceuticals' license of ruxotemitide covers dermatological indications, including basal cell carcinoma and squamous cell carcinoma.

At Lytix Biopharma we are open to discussions on co-development and outlicensing opportunities.
Contact submission form, routing to bd@lytixbiopharma.com

Investor Relations

https://lytixbiopharma.com/investors/overview.html

Someone giving a Keynote talk
Is this externally managed?

News and Events

Ribbon Art

NO COPY CHANGES from current site

https://lytixbiopharma.com/news/press-releases.html

Contact

Internal MSC note: cmm decide art/design of this page
Ribbon Art?
General email